News and Trends 13 Jun 2023 How AI can advance research and treatment of CNS disorders …generation of treatments for diseases such as Alzheimer’s, Parkinson’s, and ALS. AI is revolutionizing drug discovery for CNS disorders AI has transformed the drug discovery process for CNS disorders by… June 13, 2023 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 25 Oct 2017 What Could RNA Therapies Do for the Treatment of CNS Disorders? …led the charge as CEO to form Amylon. The company, based in Leiden and formed only last month, focuses on CNS disorders using an ultra-genetics approach. CNS research and companies… October 25, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 Gate Neurosciences emerges from stealth to tackle CNS diseases …in 2019 by a team of neuroscience industry veterans to address the need for more effective treatments for CNS disorders, and to overcome long-standing challenges in CNS drug development. Since… August 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 14 Nov 2022 Minoryx and Neuraxpharm form alliance to get rights to new therapy for rare CNS disease …new approach for Neuraxpharm. In this strategically relevant step, the company builds on its extensive CNS expertise stemming from 35 years in the field of CNS disorders. Neuraxpharm will create… November 14, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Startup Scout 13 Oct 2017 This French Biotech is Taking On CNS Diseases of the Young and the Elderly This week we’re in Castres in the South of France to visit Neurolixis. This biotech is taking on diseases of the CNS, such as Parkinson’s, depression and schizophrenia. Mission: Neurolixis… October 13, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2022 Empyrean Neuroscience launches with $22M to target CNS disorders …system (CNS). The company, based in New York City and Cambridge, U.K., is founded on a proprietary platform designed to genetically engineer small molecule therapeutics from fungi and plants. Usman… October 18, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 EditForce and Mitsubishi Tanabi Pharma to work on gene therapy for CNS …the central nervous system (CNS) by utilizing EditForce’s pentatricopeptide repeat (PPR) protein platform technology. MTPC and EditForce aim to create potential novel pharmaceuticals for the specific CNS disease by utilizing… July 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 Research identifies new treatment target for CNS injury and neurological disease Researchers in Birmingham in the U.K. have identified a potential target for drugs to treat long-term neurological conditions like Alzheimer’s Disease and foster nerve regeneration in central nervous system injuries…. September 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 NeuShen Therapeutics closes $20M pre-A financing …and established.” CNS disorders CNS disorders are increasingly recognized as major causes of death and disability worldwide while the diagnosis and treatments have largely lagged. “Bringing breakthroughs and learnings from… September 29, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 Neuraxpharm’s expansion into the Netherlands takes it from two to 20 countries in six years …company will provide differentiated and specialty generics in the Netherlands. This is a strategically important CNS pharmaceutical market in Europe. Neuraxpharm on path to number one CNS specialist Neuraxpharm Netherlands… December 7, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 Alpha Biopharma announces completion of phase 2/3 clinical study for drug to treat lung cancer …enrollment of 492 patients. The clinical and preclinical data of Zorifertinib have shown its high blood-brain barrier penetration, anti-tumor activity in metastatic CNS lesions, overall efficacy in both CNS and… August 25, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Best in Biotech 25 Nov 2025 11 neuroscience biotech companies you should know about Developing treatments for neurological diseases presents a huge challenge for neuroscience companies within the biotech industry. The central nervous system (CNS) is extremely complex, and many neurological diseases can be… November 25, 2025 - 16 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email